TY - JOUR
AU - Padhani, Anwar
AB - Targ Oncol (2017) 12:229–234 DOI 10.1007/s11523-017-0477-6 SHORT COMMUNICATION Splenic Enlargement and Bone Marrow Hyperplasia in Patients Receiving Trastuzumab-Emtansine for Metastatic Breast Cancer 1 1 2 1 Michael Kosmin & Andreas Makris & Noorulhuda Jawad & David Woolf & 1 2 David Miles & Anwar R. Padhani Published online: 21 January 2017 Springer International Publishing Switzerland 2017 Abstract 543 μm /s, p = 0.11). No changes to portal vein diameter Background An association between trastuzumab-emtansine were seen. (T-DM1) and splenic enlargement is reported in preclinical Conclusions Previously unreported increases in splenic data, and has been noted anecdotally in patients receiving volume and bone marrow hyperplasia are observed on T-DM1 at our institution. Use of whole-body MRI examina- WB-MRI in patients on T-DM1 therapy. Caution must tions (WB-MRI) allows for detailed bone marrow assessment be applied to avoid misinterpreting T-DM1-induced bone and semi-automated splenic volume calculations. marrow hyperplasia as diffuse disease progression in Objective To retrospectively evaluate changes in splenic vol- bone. ume versus evidence of bone marrow hyperplasia and/or changes in portal venous pressure in patients receiving Key points T-DM1 for metastatic breast cancer. Patients and Methods Twelve metastatic breast cancer pa- Increases in splenic volume and bone marrow tients 
TI - Splenic Enlargement and Bone Marrow Hyperplasia in Patients Receiving Trastuzumab-Emtansine for Metastatic Breast Cancer
JF - Targeted Oncology
DO - 10.1007/s11523-017-0477-6
DA - 2017-01-21
UR - https://www.deepdyve.com/lp/springer-journals/splenic-enlargement-and-bone-marrow-hyperplasia-in-patients-receiving-6XsbRu5Ldq
SP - 229
EP - 234
VL - 12
IS - 2
DP - DeepDyve
ER -